Research Article Details
| Article ID: | A23275 |
| PMID: | 23907039 |
| Source: | Int J Cardiol |
| Title: | RBBB is associated with an increased risk of NAFLD in young healthy individuals. |
| Abstract: | BACKGROUND: The pathogenesis of nonalcoholic fatty liver disease has not been fully elucidated. The most widely supported theory implicates insulin resistance as the key mechanism leading to hepatic steatosis, and perhaps also to steatohepatitis. Also one of causes of NAFLD is central congestion and hepatic injury. RBBB can associated with right ventricular dissynchrony that lead to minimal congestion in liver. So the aim of this study was to test the hypothesis that RBBB as diagnosed by ECG predicts subsequent NAFLD as diagnosed by ultrasonography (the most widely used imaging test for diagnosing hepatic steatosis). MATERIALS AND METHODS: Between March 2012 and March 2013, 2200 male subjects underwent electrocardiography (ECG) at our Medical Check-up Center for general young health screening. Of them, 220 subjects had RBBB. All analyses were performed using statistical package SPSS 15.0 and statistical significance was assessed at the two-tailed 0.05 threshold. RESULTS: Among the 2200 subjects evaluated, 220 had RBBB. The mean age, BMI, triglycerides, hemoglobin, and aspartate aminotransferase level, the mean HDL cholesterol, alanine aminotransferase, platelet count, %VC, and FEV1/FVC were not different between two groups. The group with RBBB had 66 subjects with NAFLD (30%). The group without RBBB had 44 subjects with NAFLD (2.2%). There were significant differences between the two groups(p < 0.001). CONCLUSION: RBBB is associated with an increased risk of NAFLD in young healthy individuals. |
| DOI: | 10.1016/j.ijcard.2013.07.035 |
| Strategy ID | Therapy Strategy | Synonyms | Therapy Targets | Therapy Drugs | |
|---|---|---|---|---|---|
| S01 | Improve insulin resistance | insulin sensitizer; insulin resistance; glucose tolerance | Biguanide: increases 5-AMP activated protein kinase signaling; SGLT-2 inhibitor; Thiazalidinedione: selective PPAR-γ agonists; GLP-1 agonist | Metformin; Empagliflozin; Canagliflozin; Rosiglitazone; Pioglitazone; Liraglutide | Details |
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I05 | 9352 | Type 2 diabetes mellitus | A diabetes that is characterized by chronic hyperglycaemia with disturbances of carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, insulin action, or both. A diabetes mellitus that is characterized by high blood sugar, insulin resistance, and relative lack of insulin. http://en.wikipedia.org/wiki/Diabetes, http://en.wikipedia.org/wiki/Diabetes_mellitus_type_2 | disease of metabolism/inherited metabolic disorder/ carbohydrate metabolic disorder/glucose metabolism disease/diabetes/ diabetes mellitus | Details |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress | |
|---|---|---|---|---|---|---|---|
| D199 | L-alanine | Chemical drug | DB00160 | KYNU | -- | Failed in clinical trials | Details |
| D182 | Insulin | Biological drug | DB00030 | INSR agonist; CPE modulator&product of | -- | Under clinical trials | Details |
| D248 | Obeticholic Acid | Chemical drug | DB05990 | NR1H4 activator; NR1H4 agonist; FXR agonist | Enhance lipid metabolism | Approval rejected | Details |
| D094 | Cysteamine | Chemical drug | DB00847 | GSS stimulant | Renal drug | Under clinical trials | Details |
| D095 | Cysteamine bitartrate | Chemical drug | DB00847 | -- | -- | Under clinical trials | Details |